PFIZER WINS US LIPITOR PATENT CASE

Reuters reports that generic drug manufacturer Ranbaxy has failed in its attempt to get Pfizer’s US patents in its LIPITOR anti-cholesterol drug invalidated. The decision by a US federal judge means that Ranbaxy cannot launch a generic version of LIPITOR at present. As a result, its share price has dropped by almost 9%, while the share prices of big pharmaceutical companies, including some that were not involved in the litigation, have risen. Ranbaxy have announced that it intends to appeal.


The IPKat notes that this result mirrors Pumfrey J’s decision to uphold the validity of the UK patents for LIPITOR held by Pfizer in October.

PFIZER WINS US LIPITOR PATENT CASE PFIZER WINS US LIPITOR PATENT CASE Reviewed by Anonymous on Monday, December 19, 2005 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Powered by Blogger.